Research Article

Metformin Reduces Lipotoxicity-Induced Meta-Inflammation in β-Cells through the Activation of GPR40-PLC-IP3 Pathway

Ximei Shen 1,2, Beibei Fan 1, Xin Hu 1, Liufen Luo 1, Yuanli Yan 1, and Liyong Yang 1,2

1Endocrinology Department, The First Affiliated Hospital of Fujian Medical University, Fuzhou, 350005 Fujian, China
2Diabetes Research Institute of Fujian Province, Fuzhou, 350005 Fujian, China

Correspondence should be addressed to Liyong Yang; liyongy@medmail.com.cn

Received 15 May 2019; Revised 1 August 2019; Accepted 4 September 2019

Academic Editor: Alexander Kokkinos

Copyright © 2019 Ximei Shen et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Background and Purpose. Metformin, a widely used antidiabetic drug, has been shown to have anti-inflammatory properties; nevertheless, its influence on β-cell meta-inflammation remains unclear. The following study investigated the effects of metformin on meta-inflammatory in β-cells and whether the underlying mechanisms were associated with the G protein-coupled receptor 40-phospholipase C-inositol 1, 4, 5-trisphosphate (GPR40-PLC-IP3) pathway.

Materials and Methods. Lipotoxicity-induced β-cells and the high-fat diet-induced obese rat model were used in the study. Results. Metformin-reduced lipotoxicity-induced β-cell meta-inflammatory injury was associated with the expression of GPR40. GPR40 was involved in metformin reversing metabolic inflammation key marker TLR4 activation-mediated β-cell injury. Furthermore, downstream signaling protein PLC-IP3 of GPR40 was involved in the protective effect of metformin on meta-inflammation, and the above process of metformin was partially regulated by AMPK activity. In addition, the anti-inflammatory effects of metformin were observed in obese rats. Conclusion. Metformin can reduce lipotoxicity-induced meta-inflammation in β-cells through the regulation of the GPR40-PLC-IP3 pathway and partially via the regulation of AMPK activity.

1. Introduction

Metformin has been widely used for the treatment of type 2 diabetes. Metformin exerts its effects through AMPK activation. Increasing evidence indicates that metformin directly acts on pancreatic β-cells [1]; nevertheless, the effect of metformin on β-cells remains controversial. Studies have shown that metformin inhibits β-cell apoptosis induced by hyperglycemia or hyperlipidemia [2, 3] and enhances the number of pancreatic progenitor cells in the mouse embryonic pancreas [4], while other studies have indicated that metformin has a dual role in MIN6 pancreatic β-cell function through the AMPK-dependent autophagy pathway [5]. Therefore, the exact regulation mechanisms of metformin on β-cells need to be further investigated.

Metabolic inflammatory injury is currently considered an important mechanism for lipotoxicity-induced β-cell injury. However, targeted interventions have not yet been identified. Toll-like receptor 4 (TLR4) is the key marker of meta-inflammation which has an important role in the pathogenesis of metabolic inflammation in type 2 diabetes [6–10]. Our previous studies have demonstrated that lipotoxicity directly activates the TLR4-JNK pathway cascade in islet β-cells and that it induces insulin secretion disorders and apoptosis of β-cells [11]. Whether the protective effect of metformin on β-cells is associated with TLR4 has not yet been reported. Studies have suggested that metformin has a clear inhibitory effect on TLR4 in the skeletal muscle of diabetic rats [12]. The aim of this study was to investigate whether metformin could inhibit the activation of TLR4 inflammatory signals in β-cells induced by lipotoxicity.

GPR40 is a long-chain FFA receptor that is specifically expressed on the membrane of pancreatic β-cells [13]. Although the early literatures reported that GPR40 has
inconsistencies in beta cell dysfunction [14–16], many studies supported the benefit of GPR40 on beta cells [17, 18]; and GPR40 agonist was already tested in several clinical trials [19–21]. At present, the association between the protective effects of metformin and GPR40 has not yet been reported. However, preclinical studies have demonstrated that a combination therapy with GPR40 agonist TAK-875 and metformin could be a valuable strategy for glycemic control and beta-cell preservation in type 2 diabetes [22]. This study is aimed at further exploring the relationship between GPR40 and the protective effects of metformin on lipotoxicity-induced metabolic inflammation.

In summary, beta-cell lines and high-fat diet-induced obese rats were employed to investigate the protective effects of metformin on lipotoxicity in beta-cells and the relationship between this protective effect and GPR40. Furthermore, it was confirmed that metformin inhibits lipotoxicity-induced TLR4 activation through the GPR40 pathway and AMPK activity, thereby preventing lipotoxicity-induced apoptosis of beta-cells.

2. Materials and Methods

2.1. Cell Culture. Mouse islet cell line beta TC6 was obtained from the American Type Culture Collection (Manassas, VA, USA). Cells were incubated with Dulbecco’s modified Eagle’s medium (DMEM, 25 mM/L glucose), supplemented with 10% fetal bovine serum (FBS), 2 mM/L L-glutamine, and 10 mM/L HEPES buffer solution in a humidified atmosphere containing 5% CO2/95% air at 37°C. All reagents were purchased from Gibco (Carlsbad, USA). Cells at passages 26 to 30 were used for all experiments.

2.2. In Vitro Cell Experiments

2.2.1. Palmitic Acid (PA) or Lipopolysaccharide (LPS) Treatment. beta TC6 cells were incubated in DMEM (25 mM/L glucose) for 24 h until the cells reached 50% confluence. Cell culture medium was then removed and washed twice with PBS then treated with 0.5 mM/L PA (Sigma-Aldrich) or 1.0 mg/L LPS (Sigma-Aldrich) for 24 h in culture media. Cells treated with 0.5% BSA/ethanol in HDMEM without PA or LPS (uninduced) served as the control. PA and LPS solutions were prepared as described before [11].

2.2.2. Metformin (MF) Treatment. beta TC6 cells were treated with 0.5 mM/L PA+DMEM (25 mM/L glucose) or 1.0 mg/L LPS+DMEM (25 mM/L glucose) for 24 h and then exposed to different concentrations (25, 50, and 100 μmol/L) of metformin (dissolved in 0.1% dimethylsulfoxide (DMSO) (v/v); BN1504091105; Chia Tai Tianqing, China) [23] with complete medium for 72 h. PA-induced or LPS-induced cells without metformin and uninduced cells exposed to metformin served as controls.

2.2.3. GPR40 Agonist and Inhibitor Treatment. beta TC6 cells were pretreated with 1.0 mg/L LPS for 24 h. Afterwards, cells were washed twice with PBS and then treated with 10 μmol/L of TAK-875 (dissolved in 0.1% DMSO (v/v); TRC-CANADA) [24] or 5 μmol/L of DC260126 (dissolved in 0.1% DMSO (v/v); TRC-CANADA) [25] for 72 h. LPS-induced cells without TAK-875 or DC260126 and uninduced cells exposed to TAK-875 or DC260126 served as controls.

2.2.4. Protein Inhibitor Treatments. beta TC6 cells were pretreated with 20 μmol/L PLC inhibitor (U73122, Sigma-Aldrich) [26] or 20 μmol/L IP3 inhibitor (2-APB, Sigma-Aldrich) [27], respectively, for 4 h before being exposed to 0.5 mM/L PA+DMEM (25 mM/L glucose)+100 μmol/L MF for 72 h. Cells exposed to U73122, 2-APB, or complete medium alone were used as controls.

2.2.5. AMPK Inhibitor and Agonist Treatment. beta TC6 cells were pretreated with 10 μmol/L AMPK inhibitor (compound C; Sigma-Aldrich, USA) [28] for 4 h before being exposed to 0.5 mM/L PA+DMEM (25 mM/L glucose)+100 μmol/L MF for 72 h. Cells exposed to compound C or complete medium alone were used as controls.

2.2.6. ITT and IPGTT

2.6.1. Insulin Tolerance Test (ITT). All animals were fasted for 4 hours. Insulin was injected at 1 U/kg [31]. Blood glucose...
was measured before and 0, 30, 60, 90, and 120 min after the injection of insulin.

2.6.2. Intrapерitoneal Glucose Tolerance Test (IPGTT). Intrapерitoneal glucose tolerance test was performed according to a previously described protocol [32]. Briefly, rats were fasted for 8 hours. Then, all animals received an intraperitoneal injection of 50% glucose (2 g/kg). Blood glucose and insulin were measured before and 0, 30, 60, 90, and 120 min after the injection of glucose. After the experiment, the feed was supplemented.

2.7. Serum Insulin, FFA, and Biochemical Indicator Measurements. Control and experimental rats were fasted overnight for 8 hours and then euthanized by intraperitoneal injection of 10% chloral hydrate (0.03 mL/kg). Blood samples were obtained from the abdominal aorta (serum tube, without anticoagulant); samples were centrifuged at 3500 rpm for 10 minutes at room temperature and then separated and stored at -80°C. Blood samples were used to measure fasting plasma glucose, fasting plasma insulin, free fatty acid (FFA), triglycerides (TG), total cholesterol (TC), HDL cholesterol (HDL-C), and LDL cholesterol (LDL-C), based on previously published methods [11].

2.8. Enzyme-Linked Immunosorbent Assay

2.8.1. Inflammatory Cytokine Measurements. Interleukin-1 (IL-1), interleukin-6 (IL-6), and tumor necrosis factor-α (TNF-α) were detected by ELISA (Cusabio, China). Intra-assay coefficient of variation was <8% and interassay coefficient of variation was <10%.

2.8.2. Cellular IP3 Measurements. Cellular IP3 detection referenced the ELISA instructions (Cusabio, catalog number CSB-E13420m, http://www.cusabio.com,) and documentary reports by Li et al. [33]. Cells were thoroughly washed with precooled PBS (pH 7.2 to 7.4), then transferred to a suitable centrifuge tube, diluted with 1 x PBS (pH 7.2 to 7.4) to a cell concentration of 100 million/mL, and stored at -20°C overnight. Repeat freeze-thaw cycles were used to disrupt the cell membrane. The lysed cells were then centrifuged at 1000 g for 2 min at 2-8°C, and the supernatant was used for analysis. Anti-IP3 detection antibody was added to the supernatant and incubated at 37°C for 1 hour and then incubated with substrate solution at 37°C for 15 min. The reaction was terminated following the addition of stop solution, and the OD value was measured at a wavelength of 450 nm using a microplate reader. Using the standard concentration as the ordinate (logarithmic coordinate) and the corresponding OD value as the abscissa (logarithmic coordinate), the standard curve was drawn using GraphPad Prism 5 software and the concentration for each sample was calculated.

2.9. Apoptosis Analysis by TUNEL Assay

2.9.1. Detection of βTC6 Cell Apoptosis. The TUNEL was performed using the DeadEnd™ Fluorometric TUNEL System (DeadEnd™ Fluorometric TUNEL System, Promega Corporation, USA), according to the previously published method [11]. Mechanism: the DeadEnd™ Fluorometric TUNEL System measures the fragmented DNA of apoptotic cells by catalytically incorporating fluorescein-12-dUTP at 3′-OH DNA ends using the Terminal Deoxynucleotidyl Transferase, Recombinant, enzyme (rTdT), which forms a polymeric tail using the principle of the TUNEL (TdT-mediated dUTP Nick-End Labeling) assay. The fluorescein-12-dUTP-labeled DNA then can be visualized by fluorescence microscopy or quantified by flow cytometry. In addition, the nucleus is stained with red fluorescence by PI (https://www.promega.com.cn).

2.9.2. Apoptosis Detection in Pancreatic Tissue Samples. Paraffin sections of pancreatic tissue were dewaxed and hydrated and then washed twice with xylene for 5 min. Tissue samples were then treated with different concentrations of ethanol (100, 95, 90, 80, and 70%) for 3 minutes and then treated with 1% Triton-100 and 3% H₂O₂-methanol solution for 15 min. Consequently, samples were treated with proteinase K at 37°C for 30 min. Streptavidin-FITC-labeled working solution was added to each section, and the reaction was incubated in a humidified chamber at 37°C for 1 h in the dark. Afterwards, each slide was dripped in prepared DAPI dye solution for 5 min at room temperature in the dark. Apoptotic cells were observed by fluorescence microscopy and imaged.

2.10. Protein Extraction and Western Blotting

2.10.1. Protein Extraction. Whole cell and nuclear extracts were prepared for Western blot analysis. Control and experimental rats were fasted overnight for 8 h and then euthanized by intraperitoneal injection of 10% chloral hydrate (0.03 mL/kg). Islets were isolated from each SD rat pancreas according to previously described approach [11]. Samples were then washed twice with PBS and lysed in radioimmuno precipitation assay buffer containing 50 mM Tris (pH 7.4), 150 mM NaCl, 1% Triton X-100, 1% sodium deoxycholate, and 0.1% SDS with protease inhibitors on ice for 30 min.

2.10.2. Western Blotting. Protein concentration from cells and islet tissue was determined by bicinchoninic acid protein assays. Protein samples were separated by SDS-polyacrylamide gel and transferred to a polyvinylidene fluoride (PVDF) membrane (Sigma). Membranes were blocked with 5% fat-free milk in Tris-buffered saline (TBS) containing 0.1% Tween-20 and incubated overnight at 4°C with anti-TLR4 (1:1000, Abcam, UK, ab13867), anti-NF-κB p65 (1:1000, Abcam, UK, ab16502), anti-GRP40 (1:1000, Abcam, UK, ab16502), anti-PLC (1:1000, Abcam, UK, ab243181), anti-pAMPKα1 (1:1000, Abcam, UK, ab23875), anti-AMPK (1:500, Abcam, UK, ab3759), or anti-β-actin antibody (1:200, Abcam, UK, ab8226). Membranes were then incubated with horseradish peroxidase-labeled secondary antibody (1:500) for 1 h at room temperature. Protein signals were visualized using the enhanced chemiluminescence detection system.

2.11. Immunofluorescence. Pancreatic paraffin sections from each group were dewaxed, hydrated, and pretreated using the heat-induced antigen retrieval technique. Each section was enzyme inactivated using 3% H₂O₂ in methanol for
Figure 1: Continued.
10 min and blocked with ready-to-use goat serum for 20 min. The sections were then incubated with 1:50 diluted primary antibody (anti-insulin and anti-glucagon) incubated in a wet box for 2 hours at 37°C and 1:50 diluted second antibody FITC/TRITC incubated in the dark for 1 hour at 37°C. Each slice was then incubated in prepared DAPI dye solution for 5 min at room temperature in the dark and then sealed with antiextraction sealant. Cellular protein expression was observed under a fluorescence microscope, and three random regions were imaged.

2.12. Statistical Analysis. Results were expressed as mean ± S.E. Comparisons between groups were performed using ANOVAs. The LSD test was performed to compare the two groups. P < 0.05 was considered to be statistically significant.

3. Results

3.1. The Protective Effect of Metformin on Lipotoxicity-Induced Meta-Inflammation in β-Cells Is Regulated by the GPR40 Expression. To observe the effect of metformin on β-cell lipotoxicity injury, lipotoxicity-injured β-cells were incubated with different concentrations of metformin, and TLR4 expression was assessed as a marker of meta-inflammation. We observed that metformin decreased apoptosis of β-cells (Figure 1(a)) in a concentration-dependent manner and increased insulin secretion, BIS, and GSIS (Figure 1(b)). Simultaneously, metformin concentration-dependently increased expression of GPR40 and decreased TLR4 and NF-κB overexpression (Figure 1(d)) or silencing of GPR40 in β-cells (Figure 1(e)). Our results showed that the upregulation of GPR40 improved the effect of metformin on lipotoxicity-induced apoptosis (Figure 1(f)), increased BIS and GSIS (Figure 1(g)), and reduced inflammation-related protein expression (Figure 1(h)). Conversely, the downregulation of GPR40 decreased the protective effects of metformin on β-cells (Figures 1(f)–1(h)).

3.2. GPR40 Was Involved in Metformin Reversing Metabolic Inflammation Key Marker (TLR4) Activation-Mediated β-Cell Injury. Next, we investigated the specificity of the relationship between protective effects of metformin and metabolic inflammation key marker TLR4. We used LPS,
Figure 2: Continued.
a specific agonist of TLR4, to induce β-cell inflammatory injury and then treated cells with metformin. We found that metformin improved LPS-induced inflammatory apoptosis in β-cells (Figure 2(a)), increased insulin secretion (Figure 2(b)) and GPR40 expression, and inhibited the expression of TLR4 and NF-κB subunit P65 (Figure 2(c)) in a concentration-dependent manner.

We then used lentivirus-mediated silencing or overexpression of GPR40 to verify the effect of GPR40 expression on metformin’s protective role in LPS-injured β-cells. Our results demonstrated that the upregulation of GPR40 improved the effect of metformin on LPS-induced apoptosis (Figure 2(d)), increased BIS and GSIS (Figure 2(e)), and reduced inflammation-related protein expression (Figure 2(f)). Conversely, the downregulation of GPR40 attenuated the protective effect of metformin on β-cells (Figures 2(d)–2(f)).

To further confirm the effect of GPR40 on β-cell inflammatory injury, we treated cells with GPR40 agonists or inhibitors after LPS-induced β-cell inflammatory injury. Activation of GPR40 improved lipotoxic-induced apoptosis (Figure 2(g)), increased BIS and GSIS (Figure 2(h)), and decreased expression of TLR4 and NF-κB subunit P65 (Figure 2(i)); and inhibition of GPR40 activity significantly aggravated the inflammatory injury of LPS on β-cells (Figures 2(j)–2(l)).

3.3. Downstream Target of GPR40 (PLC-IP3) Is Involved in the Protective Effect of Metformin on Lipotoxicity Inflammatory β-Cells. We then investigated the possible association of GPR40 downstream signaling (PLC-IP3) with metformin treatment. We first observed the effect of metformin on PLC-IP3 and then used PLC-IP3 specific inhibitors to interfere with the effects of metformin on lipotoxicity in β-cells. Our results showed that metformin concentration-dependently increased the level of IP3 in β-cells (Figure 3(a)) and PLC (Figure 3(b)) expression. Inhibition of PLC or IP3 reduced the protective effect of metformin on lipotoxicity inflammatory β-cells, which was characterized by increased apoptosis of lipotoxicity inflammatory β-cells (Figures 3(c) and 3(f)), decreased insulin secretion (Figures 3(d) and 3(g)), reduced expression of GPR40, and increased expression of TLR4 and NF-κB subunit P65 (Figures 3(e) and 3(h)).

3.4. The Protective Effect of Metformin on Lipotoxicity Was Partially Regulated by AMPK Activity. First, we observed the effect of metformin on AMPK activity in lipotoxicity β-cells and found that metformin can increase the activation of AMPK in a concentration-dependent manner (Figure 4(a)). Consequently, we investigated whether the AMPK inhibitor compound C may interfere with the effect of metformin on lipotoxicity. Our data suggested that the inhibition of AMPK activity partially reduced the protective effect of metformin (Figures 4(b)–4(e)). Furthermore, we examined the effect of AMPK specific activator AICAR on lipotoxicity β-cells. We found that AICAR inhibits β-cell apoptosis (Figure 4(f)), improves insulin secretion (Figure 4(g)), increases GPR40-IP3-PLC expression, and inhibits TLR4 and NF-κB subunit P65 expression (Figures 4(h) and 4(i)).
Figure 3: Continued.
rate of apoptosis in β-cells. Representative of at least 3 experiments. Metformin concentration-dependently increased the expression of PLC (a) and IP3 (b) in β-cells. We discovered that the GPR40 expression alters metformin protective function on lipotoxicity. In this study, we found that metformin could reduce the decrease cell apoptosis, and inhibit the activation of metabolic inflammation key marker (TLR4-NF-κB). In addition, we observed that metformin decreased the pancreatic cell apoptosis induced by HFD (Figure 5(o)), increased the levels of IP3 (Figure 5(p)) and the expression of GPR40, PLC, and pAMPKα1, inhibited the expression of TLR4 and NF-κB subunit P65 (Figure 5(q)), and improved the distribution and quantity of α-cells and β-cells in the pancreas (Figure 5(r)).

4. Discussion

In this study, we found that metformin could reduce the lipotoxicity-induced insulin secretion deficiency in β-cells, decrease cell apoptosis, and inhibit the activation of metabolic inflammation key marker (TLR4-NF-κB). In addition, we discovered that the GPR40 expression alters metformin’s protective function on lipotoxicity β-cells. We also found that GPR40 affected metformin’s role in inhibiting activated TLR4-induced β-cell injury. Furthermore, downstream signaling protein PLC-IP3 of GPR40 was involved in the protective effect of metformin on meta-inflammation, and the above process of metformin was partially regulated by AMPK activity. We also observed that metformin could reduce body weight and inflammatory-related factors, improve β-cell function, increase GPR40-PLC-IP3 expression, and inhibit activation of the TLR4-NF-κB pathway in an obese rat model.

The present study showed that metformin has a direct protective effect on lipotoxicity β-cells. Yet, the administration of metformin alone did not cause a decrease in cells or an increase in insulin secretion. This phenomenon is consistent with the clinic findings, which indicated that metformin alone does not increase the risk of hypoglycemia in diabetic patients [34]. Hence, metformin could be administered to nondiabetic patients, such as patients with fatty liver [35] and polycystic ovary syndrome (PCOS) [36], without causing hypoglycemia. Moreover, clinical studies have suggested that metformin has a protective effect on β-cells, independent of its hypoglycemic effect [37]. These data suggest that metformin has an additional protective effect on β-cells; however, the specific mechanisms need to be investigated [38, 39].

Furthermore, we examined whether GPR40 was involved in metformin’s lipotoxicity protection. Our results demonstrated that high expression of GPR40 was directly associated with the protective effect induced by metformin, while its inhibition reduced the effects of metformin. So far, a number of studies, including our previous work, have confirmed the benign intervention of GPR40 on β-cells [11, 40] and the protective effect of GPR40 on islet β-cells [41]. In addition, decreased GPR40 expression was found in diabetic patients.
Figure 4: Continued.
The relationship between metformin-regulated lipotoxicity and AMPK inhibitor. (b) The rate of apoptosis in β-cells. (c) Levels of BIS and GSIS. (d) Expression of IP3 in β-cells. (e) Expression levels of TLR4, NF-kB subunit P65, and GPR40. (f–i) Effect of AICAR on PA-induced β-cell injury. (f) The rate of apoptosis in β-cells. (g) Levels of BIS and GSIS. (h) Expression of IP3 in β-cells. (i) Expression levels of TLR4, NF-kB subunit P65, and GPR40. (a) \(^{\wedge}P < 0.05\) vs. NC group (without PA and MF), \(^{\wedge}P < 0.05\) vs. 0.5 mmol/L PA group, \(^{\wedge}P < 0.05\) vs. 0.5 mmol/L PA+25 μmol/L MF group, and \(^{\wedge}P < 0.05\) vs. 0.5 mmol/L PA+50 μmol/L MF group. (b–e) \(^{\wedge}P < 0.05\) vs. NC group, \(^{\wedge}P < 0.05\) vs. 0.5 mmol/L PA+100 μmol/L MF group, and \(^{\wedge}P < 0.05\) vs. 10 μmol/L compound C group. (f–i) \(^{\wedge}P < 0.05\) vs. NC group, \(^{\wedge}P < 0.05\) vs. 1.0 mmol/L AICAR group, and \(^{\wedge}P < 0.05\) vs. 0.5 mmol/L PA+1.0 mmol/L AICAR group.

The exact mechanisms through which GPR40 mediates metformin-regulated β-cell lipotoxicity inflammatory injury still remain unclear. PLC-IP3 is a downstream signaling pathway of GPR40, which regulates β-cell insulin secretion [45]. Our previous study has shown that PLC is involved in GPR40-mediated pioglitazone antagonism of lipotoxic β-cell apoptosis and oxidative stress [24]. Several other studies have also shown that PLC-IP3 is involved in GPR40-mediated DHA-induced neuronal differentiation and neurite outgrowth in adult rat stem cells [46]. In this study, we further verified that PLC-IP3 is involved in the mediating effects of GPR40 on metformin. There are several publications supporting our findings; existing studies have suggested that palmitate-induced ER Ca (2+) depletion by PLC-IP3R signaling upregulates ER stress proteins and that mitochondrial dysfunction leads to beta cell dysfunction. In addition, studies have reported that metformin has protective effects on palmitic acid-induced ER-mitochondrial dysfunction [47]. Another study performed in breast cancer patients found that metformin inhibited the activity of PLC [48], which is inconsistent with our findings. We hypothesized that the possible reason was the cell-specific or bidirectional effects of metformin on cells; metformin may inhibit tumor cell growth by inhibiting the activity of PLC. In our study, metformin alleviated β-cell apoptosis induced by lipotoxicity via PLC.

Next, we investigated whether the GPR40-PLC-IP3 pathway was mediated or affected by the AMPK activation. Our results indicated that metformin could suppress the formation of fat by regulating the activity of Runx2 and PPARγ [49]. This effect appears to be independent of the activity of AMPK.
Figure 5: Continued.
and pAMPKα1, and inhibited the activation of TLR4-NF-κB in HFD-induced obese SD rats. In order to further explain the effect of metformin on islet beta-cell function, we used statistics to control the effects of weight and insulin resistance, and we analyzed the effect of metformin on islet β-cells. The results showed that the protective effect of metformin on islet cell function was still present (P < 0.05, see supplementary materials 1). Our results suggested that metformin could improve β-cell function. Other studies have also reported the direct improvement of metformin in animal and human β-cells [50, 51], which further supported our experimental conclusions. However, metformin administration in normal SD rats did not affect the animal body weight or insulin secretion, which is consistent with clinical studies suggesting that metformin has self-limiting effects to reduce body weight [52]. Previous experiments have also demonstrated that metformin improves the metabolism of obese rats [53]. Our results showed that the high-fat diet caused a decrease in fasting insulin concentration in obese rats, which may be related to longer high-fat diet intervention time. Studies have suggested that the intervention time of high-fat diet is 4-8 weeks [54, 55]. And in the experiment, the high-fat diet lasted 16 weeks. Thus, we speculated that the metabolic stress induced by prolonged high-fat diet gradually leads to a decrease in islet function from decompensation to decompensation.

To sum up, we found that metformin could inhibit lipotoxicity-induced meta-inflammation damage in β-cells by regulating the GPR40-PLC-IP3 signaling pathway. Nevertheless, this study has certain limitations. Firstly, we did not investigate the mechanism of metformin acting on GPR40. Secondly, we used mouse islet cell line, which is different from islet β-cells found in humans. Third, our research lacked some negative control group, so our conclusions needed to be verified by subsequent experiments.

**Abbreviations**

AECs: Alveolar epithelial cells
AICAR: 5-Aminoimidazole-4-carboxamide1-β-D-ribofuranoside
AMPK: AMP-activated protein kinase
ANOVAs: Analyses of variance
BIS: Basal insulin secretion
DAPI: 4,6-Diamidino-2-phenylindole
DHA: Docosahexaenoic acid
DMEM: Dulbecco’s modified Eagle’s medium
DMSO: Dimethylsulfoxide
FBS: Fetal bovine serum
FFA: Free fatty acid A
GPR40: G protein-coupled receptor 40
GSIS: Glucose-stimulated insulin secretion
HbA1c: Glycosylated hemoglobin
HDL-C: High-density lipoprotein cholesterol
HEPES: Hydroxyethyl piperazine ethanesulfonic acid
HSFD: High-sugar, high-fat diet
HOMA-B: Homeostasis model assessment of beta cell function

![Image](Q1)

**Figure 5:** Protective effects of metformin on high-fat diet-induced inflammatory injury in obese rats. (a) The average weight of each treatment group. (b) Lee’s index. (c) HOMA-IR. (d) Free fatty acid A (FFA). (e) Metformin decreases the levels of IL-1, IL-6, and TNF-α. (f) IPGTT. (g) Glucose AUC of IPGTT. (h) ITT. (i) Glucose AUC of ITT for each group. (j) HOMA-B. (k) Plasma insulin levels during IPGTT. (l) The AUC for plasma insulin concentration during IPGTT. (m) Fasting blood glucose levels. (n) Blood lipid levels for each group: total cholesterol (TC), triglyceride (TG), high-density lipoprotein (HDL), and low-density lipoprotein (LDL). (o) Metformin reduces pancreatic cell apoptosis induced by high-fat diet. (O1) Representative images from fluorescent microscopy for each group. The white arrows indicate apoptotic cells. (O2) Collective analyses of all three independent experiments. (p) Metformin increases the levels of IP3. (q) Expression of TLR4, induced by high-fat diet. (r) Representative images of immunofluorescence from pancreatic tissue for each group. (Q1) The ratio of target protein to β-actin. (Q2) Representative Western blot images for each group. (Q3) The average weight of each treatment group. (Q4) Representative Western blot images for each group. AβP < 0.05 vs. NC group, AβP < 0.05 vs. HFD group.
HOMA-IR: Homeostasis model assessment to quantify insulin resistance
HOMA-S: Homeostasis model assessment of insulin sensitivity
IL-1: Interleukin-1
IL-6: Interleukin-6
IP3: Inositol 1, 4, 5-trisphosphate
IPGT: Intraperitoneal glucose tolerance test
ITT: Insulin tolerance test
JNK: c-Jun N-terminal protein kinase
LDL-C: Low-density lipoprotein cholesterol
LPS: Lipopolysaccharide
MF: Metformin
MyD88: Myeloid differentiation factor 88
NC: Normal control group
NF-κB: Nuclear factor-kappa B
NLR: Neutrophil to lymphocyte ratio
OD value: Optical density value
PA: Palmitic acid
PBS: Phosphate buffered saline
PCOS: Polycystic ovary syndrome
PLC: Phospholipase C
PVDF: Polyvinylidene fluoride
siRNA: Small interfering RNA
TC: Total cholesterol
TG: Triglycerides
TLR4: Toll-like receptor 4
TUNEL: Terminal deoxynucleoitidyl transferase-mediated nick end labeling.

Data Availability
The data used to support the findings of this study are included within the article.

Conflicts of Interest
The authors have no conflicts to disclose.

Authors’ Contributions
Ximei Shen wrote the manuscript; Liyong Yang conducted the design of the study and reviewed/edited the drafts and is the guarantor; Beibei Fan researched the data and edited the drafts; Liufen Luo and Yuanli Yan contributed to the discussion; Xin Hu cowrote the final draft. Liyong Yang is the guarantor of this work and, as such, had full access to all the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis. Ximei Shen and Beibei Fan are co-first authors.

Acknowledgments
This study was supported by the Science and Technology Innovation Joint Fund Project Fujian Province (grant number 2016Y9102) and Grants from the National Natural Science Foundation of China (grant numbers 81500632 and 81870572), Natural Science Foundation of Fujian Province (grant numbers 2019J01455 and 2015J01453), Fujian Province Higher Education Institute New Century Research Project (grant number 2018B049), and Medical Innovation Fund Project of Fujian Province (grant number 2018-CX-23).

Supplementary Materials
Metformin improved beta cell function independent of weight and insulin resistance. (Supplementary Materials)

References
[1] M. Hashemitabar, S. Bahramzadeh, S. Saremy, and F. Nejaddehbash, “Glucose plus metformin compared with glucose alone on β-cell function in mouse pancreatic islets,” Biomedical Reports, vol. 3, no. 5, pp. 721–725, 2015.
[2] J. S. Moon, U. Karunakaran, S. Elumalai et al., “Metformin prevents glucotoxicity by alleviating oxidative and ER stress-induced CD36 expression in pancreatic beta cells,” Journal of Diabetes and its Complications, vol. 31, no. 1, pp. 21–30, 2017.
[3] L. Simon-Szabó, M. Koskas, J. Mandl, G. Kéri, and M. Csala, “Metformin attenuates palmitate-induced endoplasmic reticulum stress, serine phosphorylation of IRS-1 and apoptosis in rat insulinoma cells,” PLoS One, vol. 9, no. 6, article e97868, 2014.
[4] B. Gregg, L. Elghazi, E. U. Alejandro et al., “Exposure of mouse embryonic pancreas to metformin enhances the number of pancreatic progenitors,” Diabetologia, vol. 57, no. 12, pp. 2566–2575, 2014.
[5] Y. Jiang, W. Huang, J. Wang et al., “Metformin plays a dual role in MIN6 pancreatic β cell function through AMPK-dependent autophagy,” International Journal of Biological Sciences, vol. 10, no. 3, pp. 268–277, 2014.
[6] G. S. Hotamisligil, “Inflammation, metalmalfunction and immunometabolic disorders,” Nature, vol. 542, no. 7640, pp. 177–185, 2017.
[7] L. A. Velloso, F. Folli, and M. J. Saad, “TLR4 at the crossroads of nutrients, gut microbiota, and metabolic inflammation,” Endocrine Reviews, vol. 36, no. 3, pp. 245–270, 2015.
[8] J. Wada and H. Makino, “Innate immunity in diabetes and diabetic nephropy,” Nature Reviews Nephrology, vol. 12, no. 1, pp. 13–26, 2016.
[9] W. He, T. Yuan, D. Choezom et al., “Ageing potentiates diet-induced glucose intolerance, β-cell failure and tissue inflammation through TLR4,” Scientific Reports, vol. 8, no. 1, p. 2767, 2018.
[10] Z. Zhang, L. F. Amorosa, S. M. Coyle et al., “Insulin-dependent regulation of mTORC2-Akt-FoxO suppresses TLR4 signaling in human leukocytes: relevance to type 2 diabetes,” Diabetes, vol. 65, no. 8, pp. 2224–2234, 2016.
[11] X. Shen, S. Yang, S. Yan et al., “Fetuin A promotes lipotoxicity in β cells through the TLR4 signaling pathway and the role of pioglitazone in anti-lipotoxicity,” Molecular and Cellular Endocrinology, vol. 412, pp. 1–11, 2015.
[12] L. G. Peixoto, R. R. Teixeira, D. D. Vilela et al., “Metformin attenuates the TLR4 inflammatory pathway in skeletal muscle of diabetic rats,” Acta Diabetologica, vol. 54, no. 10, pp. 943–951, 2017.
[13] L. S. Doshi, M. K. Brahma, S. G. Sayed et al., “Acute administration of GPR40 receptor agonist potentiates glucose-
stimulated insulin secretion in vivo in the rat,” *Metabolism*, vol. 58, no. 3, pp. 333–343, 2009.

[14] J. Wu, P. Sun, X. Zhang et al., “Inhibition of GPR40 protects MIN6 β cells from palmitate-induced ER stress and apoptosis,” *Journal of Cellular Biochemistry*, vol. 113, no. 4, pp. 1152–1158, 2012.

[15] K. Matsuda-Nagasaki, R. Takami-Esaki, K. Iwachidou et al., “Lack of GPR40/FFAR, does not induce diabetes even under insulin resistance condition,” *Diabetes, Obesity & Metabolism*, vol. 15, no. 6, pp. 538–545, 2013.

[16] R. Wagner, G. Kaiser, F. Gerst et al., “Reevaluation of fatty acid receptor 1 as a drug target for the stimulation of insulin secretion in humans,” *Diabetes*, vol. 62, no. 6, pp. 2106–2111, 2013.

[17] Y. J. Choi, D. Shin, and J. Y. Lee, “G-protein coupled receptor 40 agonists as novel therapeutics for type 2 diabetes,” *Archives of Pharmacal Research*, vol. 37, no. 4, pp. 435–439, 2014.

[18] H. Huang, M. H. Dai, and Y. X. Tao, “Physiology and therapeutics of the free fatty acid receptor GPR40,” *Progress in Molecular Biology and Translational Science*, vol. 121, pp. 67–94, 2014.

[19] T. Aaki, M. Hirayama, S. Hiroi, and K. Kaku, “GPR40-induced insulin secretion by the novel agonist TAK-875: first clinical findings in patients with type 2 diabetes,” *Diabetes, Obesity & Metabolism*, vol. 14, no. 3, pp. 271–278, 2012.

[20] K. Kaku, T. Araki, and R. Yoshinaka, “Randomized, double-blind, dose-ranging study of TAK-875, a novel GPR40 agonist, in Japanese patients with inadequately controlled type 2 diabetes,” *Diabetes Care*, vol. 36, no. 2, pp. 245–250, 2013.

[21] E. Leifke, H. Naik, J. Wu et al., “A multiple-ascending-dose study to evaluate safety, pharmacokinetics, and pharmacodynamics of a novel GPR40 agonist, TAK-875, in subjects with type 2 diabetes,” *Clinical Pharmacology & Therapeutics*, vol. 92, no. 1, pp. 29–39, 2012.

[22] R. Ito, Y. Tsujihata, K. Matsuda-Nagasaki, I. Mori, N. Negoro, and K. Takeuchi, “TAK-875, a GPR40/FFAR1 agonist, in combination with metformin prevents progression of diabetes and β-cell dysfunction in Zucker diabetic fatty rats,” *British Journal of Pharmacology*, vol. 170, no. 3, pp. 568–580, 2013.

[23] S. Gou, P. Cui, X. Li, P. Shi, T. Liu, and C. Wang, “Low concentrations of metformin selectively inhibit CD133+ cell proliferation in pancreatic cancer and have anticancer action,” *PLoS One*, vol. 8, no. 5, article e63969, 2013.

[24] X. Shen, L. Yang, S. Yan et al., “The effect of FFAR1 on pioglitazone-mediated attenuation of palmitic acid-induced oxidative stress and apoptosis in βTc6 cells,” *Metabolism*, vol. 63, no. 3, pp. 335–351, 2014.

[25] P. Wu, L. Yang, and X. Shen, “The relationship between GPR40 and lipotoxicity of the pancreatic β-cells as well as the effect of pioglitazone,” *Biochemical and Biophysical Research Communications*, vol. 403, no. 1, pp. 36–39, 2010.

[26] D. Zhang, L. Pan, L. H. Yang, X. K. He, X. Y. Huang, and F. Z. Sun, “Strontium promotes calcium oscillations in mouse meiotic oocytes and early embryos through InsP3 receptors, and requires activation of phospholipase and the synergistic action of InsP3,” *Human Reproduction*, vol. 20, no. 11, pp. 3053–3061, 2005.

[27] N. Jiang, Z. M. Zhang, L. Liu, C. Zhang, Y. L. Zhang, and Z. C. Zhang, “Effects of Ca2+ channel blockers on store-operated Ca2+ channel currents of Kupffer cells after hepatic ischemia/reperfusion injury in rats,” *World Journal of Gastroenterology*, vol. 12, no. 29, pp. 4694–4698, 2006.

[28] Z. Li, C. L. Ni, Z. Yao, L. M. Chen, and W. Y. Niu, “Liraglutide enhances glucose transporter 4 translocation via regulation of AMP-activated protein kinase signaling pathways in mouse skeletal muscle cells,” *Metabolism*, vol. 63, no. 8, pp. 1022–1030, 2014.

[29] X. Q. Xiong, Z. Geng, B. Zhou et al., “FDNC5 attenuates adipose tissue inflammation and insulin resistance via AMPK-mediated macrophage polarization in obesity,” *Metabolism*, vol. 83, pp. 31–41, 2018.

[30] A. A. Alhaider, H. M. Korashy, M. M. Sayed-Ahmed, M. Mobark, H. Klourey, and M. A. Mansour, “Metformin attenuates streptozotocin-induced diabetic nephropathy in rats through modulation of oxidative stress genes expression,” *Chemico-Biological Interactions*, vol. 192, no. 3, pp. 233–242, 2011.

[31] F. Gao, X. Zhang, L. Zhou et al., “Type 2 diabetes mitigation in the diabetic Goto–Kakizaki rat by elevated bile acids following a common-bile-duct surgery,” *Metabolism*, vol. 65, no. 2, pp. 78–88, 2016.

[32] A. Thomas, E. Belaïdi, S. Moulin et al., “Chronic intermittent hypoxia impairs insulin sensitivity but improves whole-body glucose tolerance by activating skeletal muscle AMPK,” *Diabetes*, vol. 66, no. 12, pp. 2942–2951, 2017.

[33] H. Li, X. Q. Tan, L. Yan et al., “Multi-walled carbon nanotubes act as a chemokine and recruit macrophages by activating the PLC/IP3/CRAC channel signaling pathway,” *Scientific Reports*, vol. 7, no. 1, p. 226, 2017.

[34] B. Fruehwald-Schultes, W. Kern, K. M. Oltmanns et al., “Metformin does not adversely affect hormonal and symptomatic responses to recurrent hypoglycemia,” *The Journal of Clinical Endocrinology and Metabolism*, vol. 86, no. 9, pp. 4187–4192, 2001.

[35] E. Sofer, M. Boaz, Z. Matas, M. Mashavi, and M. Sharorgosky, “Treatment with insulin sensitizer metformin improves arterial properties, metabolic parameters, and liver function in patients with nonalcoholic fatty liver disease: a randomized, placebo-controlled trial,” *Metabolism*, vol. 60, no. 9, pp. 1278–1284, 2011.

[36] C. J. Glueck and N. Goldenberg, “Characteristics of obesity in polycystic ovary syndrome: etiology, treatment, and genetics,” *Metabolism*, vol. 92, pp. 108–120, 2019.

[37] M. Seghieri, E. Rebolos, A. Mari, L. Sciangula, C. Giorda, and E. Ferrannini, “Short course of insulin treatment versus metformin in newly diagnosed patients with type 2 diabetes,” *Journal of Clinical Medicine*, vol. 7, no. 9, p. 235, 2018.

[38] G. Patané, S. Piro, A. M. Rabauzzo, M. Anello, R. Vigneri, and F. Purrello, “Metformin restores insulin secretion altered by chronic exposure to free fatty acids or high glucose: a direct metformin effect on pancreatic beta-cells,” *Diabetes*, vol. 49, no. 5, pp. 735–740, 2000.

[39] D. Williams-Herman, L. Xu, R. Teng et al., “Effect of initial combination therapy with sitaglitin and metformin on β-cell function in patients with type 2 diabetes,” *Diabetes, Obesity & Metabolism*, vol. 14, no. 1, pp. 67–76, 2012.

[40] S. Schnell, M. Schaefer, and C. Schö, “Free fatty acids increase cytosolic free calcium and stimulate insulin secretion from beta-cells through activation of GPR40,” *Molecular and Cellular Endocrinology*, vol. 263, no. 1-2, pp. 173–180, 2007.

[41] X. V. Peng, J. F. Marcinak, M. G. Raanan, and C. Cao, “Combining the G-protein-coupled receptor 40 agonist fasilglim with sitagliptin improves glycaemic control in patients with type 2 diabetes with or without metformin: a randomized,
12-week trial,” *Diabetes, Obesity & Metabolism*, vol. 19, no. 8, pp. 1127–1134, 2017.

[42] S. Del Guerra, M. Bugliani, V. D’Aleo et al., “G-protein-coupled receptor 40 (GPR40) expression and its regulation in human pancreatic islets: the role of type 2 diabetes and fatty acids,” *Nutrition, Metabolism, and Cardiovascular Diseases*, vol. 20, no. 1, pp. 22–25, 2010.

[43] S. Zheng, X. Ren, T. Han et al., “Fenofibrate attenuates fatty acid-induced islet β-cell dysfunction and apoptosis via inhibiting the NF-κB/MIF dependent inflammatory pathway,” *Metabolism*, vol. 77, pp. 23–38, 2017.

[44] M. K. Verma, M. K. Sadasivuni, A. N. Yateesh et al., “Activation of GPR40 attenuates chronic inflammation induced impact on pancreatic β-cells health and function,” *BMC Cell Biology*, vol. 15, p. 24, 2014.

[45] H. Yamada, M. Yoshida, K. Ito et al., “Potentiation of glucose-stimulated insulin secretion by the GPR40-PLC-TRPC pathway in pancreatic β-cells,” *Scientific Reports*, vol. 6, article 25912, 2016.

[46] D. Ma, M. Zhang, C. P. Larsen et al., “DHA promotes the neuronal differentiation of rat neural stem cells transfected with GPR40 gene,” *Brain Research*, vol. 1330, pp. 1–8, 2010.

[47] H. I. Kim, J. S. Lee, B. K. Kwak et al., “Metformin ameliorates lipotoxic β-cell dysfunction through a concentration-dependent dual mechanism of action,” *Diabetes and Metabolism Journal*, vol. 43, article e41, 2019.

[48] T. A. Smith and S. M. Phyu, “Metformin decouples phospholipid metabolism in breast cancer cells,” *PLoS One*, vol. 11, no. 3, article e0151179, 2016.

[49] Y. Gao, J. Xue, X. Li, Y. Jia, and J. Hu, “Metformin regulates osteoblast and adipocyte differentiation of rat mesenchymal stem cells,” *The Journal of Pharmacy and Pharmacology*, vol. 60, no. 12, pp. 1695–1700, 2008.

[50] A. V. Matveyenko, S. Dry, H. I. Cox et al., “Beneficial endocrine but adverse exocrine effects of sitagliptin in the human islet amyloid polypeptide transgenic rat model of type 2 diabetes: interactions with metformin,” *Diabetes*, vol. 58, no. 7, pp. 1604–1615, 2009.

[51] G. Derosa, P. Maffioli, S. A. T. Salvadeo et al., “Effects of sitagliptin or metformin added to pioglitazone monotherapy in poorly controlled type 2 diabetes mellitus patients,” *Metabolism*, vol. 59, no. 6, pp. 887–895, 2010.

[52] Y. Takeshita, Y. Kita, K. Kato et al., “Effects of metformin and alogliptin on body composition in people with type 2 diabetes,” *Journal of Diabetes Investigation*, vol. 10, no. 3, pp. 723–730, 2018.

[53] M. A. Linden, K. T. Lopez, J. A. Fletcher et al., “Combining metformin therapy with caloric restriction for the management of type 2 diabetes and nonalcoholic fatty liver disease in obese rats,” *Applied Physiology, Nutrition, and Metabolism*, vol. 40, no. 10, pp. 1038–1047, 2015.

[54] C. E. Hagberg, A. Mehlem, A. Falkevall et al., “Targeting VEGF-B as a novel treatment for insulin resistance and type 2 diabetes,” *Nature*, vol. 490, no. 7420, pp. 426–430, 2012.

[55] D. S. Salmanoglu, T. Gurpınar, K. Vural, N. Ekerbicer, E. Darıverenli, and A. Var, “Melatonin and L-carnitine improves endothelial disfunction and oxidative stress in type 2 diabetic rats,” *Redox Biology*, vol. 8, pp. 199–204, 2016.